Presented Sept. 16, 2005.Click the topic below to receive emails when new articles are available. It is taken by mouth. Commenting is limited to medical professionals. You must declare any conflicts of interest related to your comments and responses. Please see our It may help with incontinence, urinary frequency, and urinary urgency. Patients not electing an increase received a placebo, because approved product labeling allowed an increase only for those receiving solifenacin.
T. Nakaki, in Side Effects of Drugs Annual, 2016.
Common side effects include dry mouth, constipation, and urinary tract infection.
It is uncle You must declare any conflicts of interest related to your comments and responses.
If you log out, you will be required to enter your username and password the next time you visit.
All patients had reported symptoms of OAB lasting three or more months.Participants received two weeks of placebo and were then randomized to receive 5 mg of solifenacin (n = 478) or 4 mg of tolterodine ER (n = 599) for four weeks.After four weeks of treatment, patients had the option to request a dose increase. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. Solifenacin, 5 mg, has less reported dry mouth than tolterodine, but at 10 mg, the incidence of dry mouth is similar. Initial dose: 5 mg orally once daily Maintenance dose: 5 to 10 mg orally once daily Use: For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency Please see our Comments on Medscape are moderated and should be professional in tone and on topic. Both solifenacin and tolterodine have good clinical efficacy. Discontinuation rates were 4.7% and 3.8% in the solifenacin and tolterodine ER groups, respectively.
Please enter a Recipient Address and/or check the Send me a copy checkbox. Of patients in the solifenacin 5 mg group, 48% elected a dose increase, and 51% of patients in the tolterodine ER group elected a dose increase at four weeks.The study, sponsored by Astellas Pharma Europe, the manufacturers of solifenacin, found that a significantly higher proportion of patients became dry after treatment with solifenacin (58.7%) compared with tolterodine ER (48.9%; In addition, at the study end point of 12 weeks, 74.1% of patients in the solifenacin group achieved a 50% or greater decrease in incontinence episodes compared with 66.5% in the tolterodine ER group ( Adverse effects expected with antimuscarinic drugs, including dry mouth, "The results of this trial clearly show that flexible dosing with solifenacin (5 mg and 10 mg) is superior to tolterodine ER in reducing incontinence, enabling patients to achieve continence, and provides tangible benefits from the patient perspective," the authors write.According to Dr. Chapple, solifenacin has a long half-life, with the theoretical disadvantage that it persists in the body for some time, "although this can also be an advantage since missing a few doses will not influence efficacy if the patient has achieved steady state. In 2 out of the 4 studies also solifenacin 5 mg was used and one of the studies included tolterodine 2 mg bid. All material on this website is protected by copyright, Copyright © 1994-2020 by WebMD LLC. However, in head—to-head trials, solifenacin seems to have somewhat better outcomes. To comment please Comments on Medscape are moderated and should be professional in tone and on topic. Randomized Controlled Trial. Solifenacin Succinate Versus Tolterodine 4mg Once Daily (STAR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Antimuscarinic therapy is effective as OAB treatment. During this period for solifenacin 5 mg and tolterodine ER 4 mg groups respectively 18.2% vs. 14.5% reported dry mouth, 3.0% vs. 1.2% reported constipation and 0.2% vs. 1.5% reported blurred vision; discontinuations were low in both groups.
Not all parameters and treatment groups were evaluated in each individual study.